Lakefront Biotherapeutics (LKFT) Cash & Equivalents (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash & Equivalents for 13 consecutive years, with $76.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 97.97% year-over-year to $76.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.0 million (down 97.97% YoY) and the FY2025 annual result came in at $100.0 million, down 97.35% from the prior year.
• Cash & Equivalents retreated to $76.0 million in Q1 2026 per LKFT's latest filing, from $100.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for LKFT reached as high as $4.0 billion in Q1 2024 and fell as low as $73.1 million in Q4 2024.
• A 5-year average of $1.4 billion and a median of $189.8 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 2766.15% — and 2026, when it plunged 97.97%.
• Year by year, Cash & Equivalents stood at $578.2 million in 2022, then tumbled by 67.17% to $189.8 million in 2023, then slumped by 61.49% to $73.1 million in 2024, then surged by 36.78% to $100.0 million in 2025, then declined by 23.97% to $76.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $76.0 million, $100.0 million, and $3.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.